Etubics Corporation (Etubics)

Oncology Corporate Profile

HQ Location

410 West Harrison Street, Suite 100
Seattle, WA 98119

Company Description

Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage biotechnology company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively known as the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ETBX-011immunotherapyColorectal cancerII
ETBX-011immunotherapyBreast cancerPreclinical
ETBX-011immunotherapyHead & Neck cancerPreclinical

View additional information on product candidates here »

Pipeline image


Recent News Headlines

There are no news items to display